Digital health companies are combining GLP-1 medications with personalized coaching, nutrition guidance, and long-term wellness support to improve patient outcomes and make treatment more sustainable
New York, 10 November 2026 – The growing demand for GLP-1 medications has created new possibilities for people managing obesity, diabetes, and other metabolic health conditions. These drugs have gained attention for their ability to support weight loss and improve blood sugar control. However, medication alone may not address the broader health challenges patients face. Digital health companies are now exploring a more comprehensive approach that combines medical treatment with lifestyle support, personalized guidance, and long-term patient care.
At the INVEST Digital Health conference held in October 2026, executives from Noom, Omada Health, Virta Health, and Twin Health discussed how their organizations are expanding GLP-1 care beyond prescriptions. Their shared approach focuses on improving overall metabolic and cardiometabolic health rather than treating weight loss as the only measure of success.
GLP-1 medications can deliver meaningful health benefits, but maintaining progress requires continued support. Patients may struggle with medication adherence, lifestyle changes, nutrition, and concerns about regaining weight after stopping treatment. Digital health platforms are addressing these challenges by connecting patients with healthcare professionals, health coaches, and personalized wellness programs.
For example, Noom combines access to prescribing doctors with coaching and tools that encourage healthier daily habits. Its approach focuses on helping patients understand their health goals while building routines that support long-term progress. Similarly, Virta Health provides nutrition guidance and lifestyle support alongside GLP-1 treatment. According to its Chief Commercial Officer, Laura Walmsley, the company reports more than 80 percent compliance and engagement among patients who remain in its program for one year.
Omada Health is taking a broader approach by addressing multiple health conditions together. Its programs combine personalized coaching, exercise guidance, nutrition support, and patient education. This model recognizes that obesity, diabetes, high blood pressure, and other metabolic conditions can be connected. Addressing these concerns together may help improve overall health while creating greater value for healthcare providers and employers.
Twin Health is also exploring how technology can make treatment more personalized. The company uses smart devices and sensors to create a digital model of an individual's health. This information helps generate tailored recommendations related to food, physical activity, sleep, and stress management. Its approach aims to improve metabolic health and potentially help some patients reduce their dependence on medication under appropriate medical supervision.
However, the growing cost of GLP-1 medications remains a concern for employers and healthcare buyers. Digital health companies believe that combining medication with lifestyle support can create better long-term outcomes and improve healthcare spending. Instead of focusing solely on prescription access, organizations are increasingly evaluating the overall value of patient care programs.
The market is also expected to become more competitive. Industry leaders anticipate consolidation as digital health companies compete to demonstrate meaningful clinical results, patient engagement, and financial value.
The future of GLP-1 care will depend on how effectively medication, technology, and human support work together. By focusing on the person rather than the prescription, digital health companies are moving toward a more connected approach to weight management and metabolic wellness. The goal is not simply to help patients lose weight, but to support healthier lives through consistent and personalized care.